330 related articles for article (PubMed ID: 33211799)
1. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Le Gouill S; Ghesquières H; Oberic L; Morschhauser F; Tilly H; Ribrag V; Lamy T; Thieblemont C; Maisonneuve H; Gressin R; Bouhabdallah K; Haioun C; Damaj G; Fornecker L; Bouhabdallah R; Feugier P; Sibon D; Cartron G; Bonnet C; André M; Chartier L; Ruminy P; Kraeber-Bodéré F; Bodet-Milin C; Berriolo-Riedinger A; Brière J; Jais JP; Molina TJ; Itti E; Casasnovas RO
Blood; 2021 Apr; 137(17):2307-2320. PubMed ID: 33211799
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.
Casasnovas RO; Ysebaert L; Thieblemont C; Bachy E; Feugier P; Delmer A; Tricot S; Gabarre J; Andre M; Fruchart C; Mounier N; Delarue R; Meignan M; Berriolo-Riedinger A; Bardet S; Emile JF; Jais JP; Haioun C; Tilly H; Morschhauser F
Blood; 2017 Sep; 130(11):1315-1326. PubMed ID: 28701367
[TBL] [Abstract][Full Text] [Related]
3. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
4. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
5. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
[TBL] [Abstract][Full Text] [Related]
6. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
8. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Casasnovas RO; Meignan M; Berriolo-Riedinger A; Bardet S; Julian A; Thieblemont C; Vera P; Bologna S; Brière J; Jais JP; Haioun C; Coiffier B; Morschhauser F;
Blood; 2011 Jul; 118(1):37-43. PubMed ID: 21518924
[TBL] [Abstract][Full Text] [Related]
9. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Micallef IN; Maurer MJ; Wiseman GA; Nikcevich DA; Kurtin PJ; Cannon MW; Perez DG; Soori GS; Link BK; Habermann TM; Witzig TE
Blood; 2011 Oct; 118(15):4053-61. PubMed ID: 21673350
[TBL] [Abstract][Full Text] [Related]
10. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas.
El Sayed R; El Darsa H; Kort J; Al Chami F; Ibrahim A; Charafeddine M; Bazarbachi A; Abou Dalle I; El Cheikh J
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):711-719. PubMed ID: 34140260
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
[TBL] [Abstract][Full Text] [Related]
13. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
Thieblemont C; Altmann B; Frontzek F; Renaud L; Chartier L; Ketterer N; Récher C; Poeschel V; Fitoussi O; Held G; Casasnovas O; Haioun C; Morschhauser F; Glass B; Mounier N; Tilly H; Rosenwald A; Ott G; Lenz G; Molina T; Ziepert M; Schmitz N
Blood Adv; 2023 Aug; 7(15):3968-3977. PubMed ID: 36716220
[TBL] [Abstract][Full Text] [Related]
16. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
Kostakoglu L; Martelli M; Sehn LH; Belada D; Carella AM; Chua N; Gonzalez-Barca E; Hong X; Pinto A; Shi Y; Tatsumi Y; Knapp A; Mattiello F; Nielsen T; Sahin D; Sellam G; Oestergaard MZ; Vitolo U; Trněný M
Blood Adv; 2021 Mar; 5(5):1283-1290. PubMed ID: 33651099
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.
Ohmachi K; Kinoshita T; Tobinai K; Ogawa G; Mizutani T; Yamauchi N; Fukuhara N; Uchida T; Yamamoto K; Miyazaki K; Tsukamoto N; Iida S; Utsumi T; Yoshida I; Imaizumi Y; Tokunaga T; Yoshida S; Masaki Y; Murayama T; Yakushijin Y; Suehiro Y; Nosaka K; Dobashi N; Kuroda J; Takamatsu Y; Maruyama D; Ando K; Ishizawa K; Ogura M; Yoshino T; Hotta T; Tsukasaki K; Nagai H;
Blood Adv; 2021 Feb; 5(4):984-993. PubMed ID: 33591324
[TBL] [Abstract][Full Text] [Related]
18. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
19. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
20.
Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
